Ovid pens deal to offload twice-failed former lead program
09 Feb 2022 //
BIOSPACE
Ovid`s Angelman syndrome therapy falls short at Phase 3
02 Dec 2020 //
PHARMAFILE
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020
23 Nov 2020 //
PRESSRELEASE
Angelini lands EU rights to Ovid`s phase 3 rare disease drug
14 Jul 2020 //
FIERCE BIOTECH
Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101
08 May 2020 //
PRESS RELEASE